ATHENS, Ga. and RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) — Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced the closing of a common stock financing totalling $10.8 million. Proceeds from the raise will support the company’s business plan through mid-2022. “This capital will allow us to continue our efforts to deliver important therapeutics to the central nervous system using a novel approach to potentially treat a number of extremely debilitating neurodegenerative diseases,” stated Dr. Mark A. Sirgo, Chief Executive Officer.


Read Full Article on Globe Newswire